Literature DB >> 2161084

Cell proliferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas and glioblastoma multiforme: a Ki-67 study.

R Raghavan1, P V Steart, R O Weller.   

Abstract

Although astrocytomas, anaplastic astrocytomas and glioblastoma multiforme differ in their clinical courses, histological distinction between these three tumours and between astrocytomas and anaplastic astrocytomas in particular may be unclear on histology alone especially in small biopsies. In the present study, a more objective way of distinguishing between the three types of tumour is sought. Frozen sections from 26 astrocytomas, 26 anaplastic astrocytomas and 38 glioblastomas were stained by an indirect immunoperoxidase technique using the monoclonal antibody Ki-67 which binds to nuclear proteins in the G1, S, G2 and M phases of the cell cycle. The Ki-67 staining was assessed quantitatively through direct observation of the stained sections by the use of a drawing tube attached to a microscope. A minimum of 1000 cells was counted in each case and labelled cells were expressed as a percentage of the total number of cells. These results, when correlated in each case with the histology of the tumour in paraffin sections, showed Ki-67 labelling indices ranging from 0 to 1.9% (mean 0.5% SD +/- 0.54) in astrocytomas, 0.6 to 10.9% (mean 4.1% SD +/- 2.8) in anaplastic astrocytomas and 0.9 to 16.2% (mean 6.4% SD +/- 3.34) in glioblastoma multiforme. The differences in the three types of tumour were statistically significant. The results suggest that Ki-67 staining is a useful addition to the panel of techniques for distinguishing between astrocytomas, anaplastic astrocytomas and glioblastoma multiforme.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161084     DOI: 10.1111/j.1365-2990.1990.tb00941.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  26 in total

1.  Grading of brain tumours. The British experience.

Authors:  R O Weller
Journal:  Neurosurg Rev       Date:  1992       Impact factor: 3.042

2.  Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.

Authors:  D Fulton; R Urtasun; P Forsyth
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

3.  Comparison of different Ki67 antibodies in human glioblastomas.

Authors:  S H Torp; E Johannesen; C F Lindboe
Journal:  Clin Mol Pathol       Date:  1995-08

Review 4.  The treatment of primary malignant brain tumours.

Authors:  I R Whittle; A Gregor
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-02       Impact factor: 10.154

5.  Proliferative activity and prognosis of low-grade astrocytomas.

Authors:  D Schiffer; P Cavalla; A Chiò; P Richiardi; M T Giordana
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

6.  Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study.

Authors:  D N Louis; S Edgerton; A D Thor; E T Hedley-Whyte
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

7.  Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiforme.

Authors:  Katarzyna Kosla; Elzbieta Pluciennik; Agata Kurzyk; Dorota Jesionek-Kupnicka; Radzislaw Kordek; Piotr Potemski; Andrzej K Bednarek
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

8.  A multi-resolution textural approach to diagnostic neuropathology reporting.

Authors:  Mohammad Faizal Ahmad Fauzi; Hamza Numan Gokozan; Brad Elder; Vinay K Puduvalli; Christopher R Pierson; José Javier Otero; Metin N Gurcan
Journal:  J Neurooncol       Date:  2015-08-09       Impact factor: 4.130

9.  The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time.

Authors:  R Schröder; K Bien; R Kott; I Meyers; R Vössing
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  Potential doubling time and tumour doubling time in meningiomas and neurinomas.

Authors:  S Nakasu; Y Nakasu; M Nakajima; M Yokoyama; M Matsuda; J Handa
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.